乳腺癌新辅助系统治疗后省略手术:影像引导活检识别病理完全缓解者的可行性试验
该单中心前瞻性试验纳入40例T1-3N0-3三阴性或HER2阳性乳腺癌患者,在新辅助系统治疗(NST)后、手术前对原发肿瘤区域行超声或钼靶引导的细针穿刺(FNA)和真空辅助空心针活检(VACB),并与手术病理比较。结果显示联合FNA/VACB预测乳腺残留癌的准确率为98%(95%CI 87%-100%),假阴性率5%(95%CI 0%-24%),阴性预测值95%(95%CI 75%-100%),VACBalone优于FNAalone(P=0.011)。
要点
- NST后影像引导FNA/VACB可准确识别乳腺pCR患者,联合准确率98%。
- VACB单独评估残留癌的准确性显著优于FNA单独(P=0.011)。
- 基于结果已启动省略乳腺手术的前瞻性临床试验。
核心结论
- NST后影像引导FNA/VACB能准确识别乳腺病理完全缓解的患者。
- 基于该结果,已启动对影像引导活检证实乳腺pCR者省略乳腺手术的前瞻性临床试验。
研究设计与样本
- 单中心前瞻性试验纳入40例T1-3N0-3三阴性或HER2阳性乳腺癌接受NST的患者。
- 手术前对原发肿瘤区域行超声或钼靶引导的FNA和VACB,并与手术标本病理比较。
主要发现
- 初始临床肿瘤中位大小3.3 cm(范围1.2-7.0 cm),16例(40%)有活检证实的淋巴结转移。
- 联合FNA/VACB预测乳腺残留癌的准确率98%(95%CI 87%-100%),假阴性率5%(95%CI 0%-24%),阴性预测值95%(95%CI 75%-100%)。
- VACB单独评估残留癌的准确性优于FNA单独(P=0.011)。
临床怎么用
- 对NST后三阴性或HER2阳性乳腺癌患者,可考虑影像引导FNA/VACB评估乳腺残留癌以识别pCR。
- VACB单独评估残留癌的准确性优于FNA单独,临床决策时可优先考虑VACB。
局限性
- 单中心前瞻性试验样本量较小(40例)。
- 联合FNA/VACB假阴性率95%CI上限达24%,阴性预测值95%CI下限为75%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted core biopsy (VACB) in assessing the presence of residual cancer in the breast after neoadjuvant systemic therapy (NST). SUMMARY BACKGROUND DATA: Pathologic complete response (pCR) rates after NST have improved dramatically, suggesting that surgery might be avoided in some patients. Safe avoidance of surgery would require accurate confirmation of no residual invasive/in situ carcinoma. METHODS: Forty patients with T1-3N0-3 triple-negative or HER2-positive cancer receiving NST were enrolled in this single-center prospective trial. Patients underwent ultrasound-guided or mammography-guided FNA and VACB of the initial breast tumor region before surgery. Findings were compared with findings on pathologic evaluation of surgical specimens to determine the performance of biopsy in predicting residual breast disease after NST. RESULTS: Median initial clinical tumor size was 3.3 cm (range, 1.2-7.0 cm); 16 patients (40%) had biopsy-proven nodal metastases. After NST, median clinical tumor size was 1.1 cm (range, 0-4.2 cm). Nineteen patients (47.5%) had a breast pCR and were concordant with pathologic nodal status in 97.5%. Combined FNA/VACB demonstrated an accuracy of 98% (95% CI, 87%-100%), false-negative rate of 5% (95% CI, 0%-24%), and negative predictive value of 95% (95% CI, 75%-100%) in predicting residual breast cancer. VACB alone was more accurate than FNA alone (P = 0.011). CONCLUSIONS: After NST, image-guided FNA/VACB can accurately identify patients with a breast pCR. Based on these results, a prospective clinical trial has commenced in which breast surgery is omitted in patients with a breast pCR after NST according to image-guided biopsy.
引用
- Kuerer HM, Rauch GM, Krishnamurthy S, et al. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018. PMID: 28549010. doi:10.1097/SLA.0000000000002313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。